Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Midatech Pharma PLC (NASDAQ: MTP).

Full DD Report for MTP

You must become a subscriber to view this report.


Recent News from (NASDAQ: MTP)

Midatech Pharma reports 1H results
Midatech Pharma (NYSE: MTP ): 1H GAAP EPS of -9p. More news on: Midatech Pharma PLC, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: September, 27 2018 06:03
Midatech Announces Proposed Sale of Midatech Pharma US Inc. ("MTP US") to Kanwa Holdings, LP an affiliate of Barings LLC
27 September 2018 Midatech Pharma PLC (" Midatech " or the " Company ") Midatech Announces Proposed Sale of Midatech Pharma US Inc. (“MTP US”) to Kanwa Holdings, LP an affiliate of Barings LLC Total consideration of up to $19m, as initial consideration of $13 m...
Source: GlobeNewswire
Date: September, 27 2018 03:00
Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera(TM) Microsphere Technology
­­ 31 August 2018 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera™ Microsphere Technology Interim data for key oncology drug ca...
Source: GlobeNewswire
Date: August, 31 2018 03:00
2007 - 2018 DGI  Vs. HYI Vs. Index Fund - Actual Performance Over 11 Years
I've been striving for years now to find a fair and objective means of testing the relative merits of: the HYI strategy of investing in investments such as CEFs, BDCs, mREITS and MLPs which pay high dividends or distributions - typically over 8% per year. the DGI approach to investing in...
Source: SeekingAlpha
Date: July, 27 2018 11:11
Midatech Pharma PLC: Trading Update
 25 July 2018 Midatech Pharma PLC (“Midatech”, “Company” or “Group”) Trading Update Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products i...
Source: GlobeNewswire
Date: July, 25 2018 03:00
Midatech Pharma US announces Co-Promotion Agreement with Bausch Health Companies Inc. for the Exclusive Right to Promote NeutraSal® to the Oncology Market in United States
23 July 2018 Midatech Pharma PLC (“Midatech”, “Company” or “Group”) Midatech Pharma US announces Co-Promotion Agreement with Bausch Health Companies Inc. for the Exclusive Right to Promote NeutraSal® to the Oncology Market in United Sta...
Source: GlobeNewswire
Date: July, 23 2018 03:11
Midatech Pharma US enrols first patient in Gelclair trial in stem cell transplant
8 June 2018 Midatech Pharma PLC (“Midatech”, “Company” or “Group”) Midatech Pharma US enrols first patient in Gelclair® trial in stem cell transplant Patients now being enrolled at the Dana-Farber/Brigham and Women’s Ca...
Source: GlobeNewswire
Date: June, 07 2018 22:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-110.20790.180.20790.1674147,046
2018-12-100.220.210.24720.195170,796
2018-12-070.250.2210.250.2198137,691
2018-12-060.230.23850.260.2399,534
2018-12-050.240.23920.250.2395,996

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-119,88372,89613.5577Cover
2018-12-104,05363,1726.4158Cover
2018-12-0731,94242,57175.0323Short
2018-12-0614,08618,02478.1514Short
2018-12-042,92423,97612.1955Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MTP.


About Midatech Pharma PLC (NASDAQ: MTP)

Logo for Midatech Pharma PLC (NASDAQ: MTP)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $22,251,118 - 05/17/2018
  • Issue and Outstanding: 30,542,068 - 12/31/2017

 


Recent Filings from (NASDAQ: MTP)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 31 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 25 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 23 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 08 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 01 2018
Specialized Disclosure Report
Filing Type: SDFiling Source: edgar
Filing Date: May, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 25 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 21 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 16 2018

 

 


Daily Technical Chart for (NASDAQ: MTP)

Daily Technical Chart for (NASDAQ: MTP)


Stay tuned for daily updates and more on (NASDAQ: MTP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MTP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MTP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MTP and does not buy, sell, or trade any shares of MTP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/